- Home
- EVER vs VRDN Comparison
EVER vs VRDN Comparison
Compare EVER & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVER
- VRDN
- Stock Information
- Founded
- EVER 2008
- VRDN 2006
- Country
- EVER United States
- VRDN United States
- Employees
- EVER N/A
- VRDN N/A
- Industry
- EVER Computer Software: Programming Data Processing
- VRDN Medical Specialities
- Sector
- EVER Technology
- VRDN Health Care
- Exchange
- EVER Nasdaq
- VRDN Nasdaq
- Market Cap
- EVER 960.3M
- VRDN 1.0B
- IPO Year
- EVER 2018
- VRDN N/A
- Fundamental
- Price
- EVER $23.81
- VRDN $13.97
- Analyst Decision
- EVER Strong Buy
- VRDN Strong Buy
- Analyst Count
- EVER 6
- VRDN 12
- Target Price
- EVER $32.50
- VRDN $38.50
- AVG Volume (30 Days)
- EVER 559.8K
- VRDN 785.8K
- Earning Date
- EVER 05-05-2025
- VRDN 05-06-2025
- Dividend Yield
- EVER N/A
- VRDN N/A
- EPS Growth
- EVER N/A
- VRDN N/A
- EPS
- EVER 1.03
- VRDN N/A
- Revenue
- EVER $575,757,000.00
- VRDN $302,000.00
- Revenue This Year
- EVER $31.67
- VRDN N/A
- Revenue Next Year
- EVER $11.31
- VRDN $21,976.14
- P/E Ratio
- EVER $23.05
- VRDN N/A
- Revenue Growth
- EVER 113.43
- VRDN 4.86
- 52 Week Low
- EVER $16.63
- VRDN $9.90
- 52 Week High
- EVER $30.03
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- EVER 47.03
- VRDN 56.41
- Support Level
- EVER $22.76
- VRDN $13.37
- Resistance Level
- EVER $23.62
- VRDN $14.18
- Average True Range (ATR)
- EVER 0.74
- VRDN 0.68
- MACD
- EVER -0.07
- VRDN 0.13
- Stochastic Oscillator
- EVER 35.68
- VRDN 75.40
About EVER EverQuote Inc.
EverQuote Inc is engaged in the business activity of offering an online marketplace for insurance shopping, connecting consumers with insurance provider customers, which includes both carriers and agents. The online marketplace offers consumers to find relevant insurance quotes based on car insurance, home insurance, and life insurance. The platform of the company is driven by data science. The firm's data and technology platform match and connects consumers seeking to purchase insurance with relevant options from its broad direct network of insurance providers. It derives a majority of revenue from Direct channels.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).